文献速递乳腺癌

SOLAR-1 中 PIK3CA 突变 HR+/HER2- 晚期乳腺癌患者报告结局

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
PubMed 文献 · J Clin Oncol · 2021-03-29

SOLAR-1 III 期试验中,341 例 PIK3CA 突变 HR+/HER2- 晚期乳腺癌患者随机接受阿培利司或安慰剂联合氟维司群,评估患者报告结局。两组总体健康状况/QoL 无显著差异,但阿培利司组腹泻、食欲下降、恶心呕吐和疲乏症状更差。

要点

  • 阿培利司组与安慰剂组总体健康状况/QoL 无统计学差异。
  • 阿培利司组腹泻、食欲下降、恶心呕吐及疲乏症状较安慰剂组恶化。
  • 阿培利司组最严重疼痛有数值改善趋势但未达统计学意义。

核心结论

  • 两组总体健康状况/QoL 恶化无统计学差异,但阿培利司组腹泻、食欲下降、恶心呕吐和疲乏症状偏向安慰剂组。

研究设计与样本

  • III 期 SOLAR-1 试验(NCT02437318)PIK3CA 突变队列,341 例患者随机 1:1 接受阿培利司 300 mg 每日或安慰剂联合氟维司群 500 mg。
  • 使用 EORTC QLQ-C30 和简明疼痛量表简表评估患者报告结局,采用重复测量模型和 Cox 模型分析。

主要发现

  • 总体健康状况/QoL 平均变化:阿培利司组 -3.50(95%CI -8.02 至 1.02),安慰剂组 0.27(95%CI -4.48 至 5.02)。
  • 总体治疗效应在总体健康状况/QoL 无显著差异(-3.77;95%CI -8.35 至 0.80;P = .101)。
  • 总体健康状况/QoL 恶化 10% 的时间两组相似(HR 1.03;95%CI 0.72 至 1.48)。
  • 第 24 周最严重疼痛数值改善:阿培利司组 42% 对安慰剂组 32%(P = .090)。

关键数值与推荐

  • 阿培利司 300 mg 每日联合氟维司群 500 mg(第 1 周期第 1、15 天及后续周期第 1 天)。

临床怎么用

  • 治疗决策需综合考虑疗效与耐受性,阿培利司组需关注腹泻、食欲下降、恶心呕吐和疲乏等症状管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed health-related quality of life using patient-reported outcome measures in these patients. MATERIALS AND METHODS: In the PIK3CA-mutant cohort, 341 patients were randomly assigned 1:1 to receive alpelisib 300 mg daily or placebo plus fulvestrant 500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles. Patient-reported outcomes were evaluated with the European Organisation for Research and Treatment of Cancer QoL of Cancer Patients and Brief Pain Inventory-Short Form questionnaires. Changes from baseline and time to 10% deterioration were analyzed using repeated measurement models and Cox models, respectively. RESULTS: Global Health Status/QoL and functional status were maintained from baseline (mean changes < 10 points) in the alpelisib (overall change from baseline [95% CI], -3.50 [-8.02 to 1.02]) and placebo arms (overall change from baseline [95% CI], 0.27 [-4.48 to 5.02]). Overall treatment effect in Global Health Status/QoL was not significantly different between arms (-3.77; 95% CI, -8.35 to 0.80; P = .101). Time to 10% deterioration for Global Health Status/QoL was similar between arms (hazard ratio, 1.03; 95% CI, 0.72 to 1.48). Compared with placebo, deterioration in social functioning and in diarrhea, appetite loss, nausea or vomiting, and fatigue symptom subscales occurred with alpelisib. Numerical improvement in Worst Pain was observed with alpelisib versus placebo (42% v 32%, week 24; P = .090). CONCLUSION: In SOLAR-1, there was no statistical difference in deterioration of Global Health Status/QoL between arms, whereas symptom subscales favored placebo for diarrhea, appetite loss, nausea or vomiting, and fatigue, known side effects of alpelisib. Treatment decisions must consider efficacy and tolerability; taken with clinical efficacy, these results support the benefit-risk profile of alpelisib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative PIK3CA-mutated advanced breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ciruelos EM, Rugo HS, Mayer IA, et al. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021. PMID: 33780274. doi:10.1200/JCO.20.01139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。